Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Drug

Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma

Fineline Cube Mar 11, 2024

Simcere Pharmaceutical Group (HKG: 2096), based in China, has received approval from the U.S. Food...

Company Drug

Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval

Fineline Cube Mar 11, 2024

Everest Medicines (HKG: 1952), based in China, has announced that its New Drug Application (NDA)...

Company Drug

Lepu Biotechnology’s MRG004A ADC Gains Fast Track Designation for Pancreatic Cancer

Fineline Cube Mar 11, 2024

Lepu Biotechnology Co., Ltd. (HKG: 2157), based in China, has announced that its in-house developed...

Company Deals

Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal

Fineline Cube Mar 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...

Company Deals

Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline

Fineline Cube Mar 11, 2024

Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...

Company Drug

ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval

Fineline Cube Mar 11, 2024

Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched...

Company Drug Legal / IP

BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement

Fineline Cube Mar 11, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has initiated patent...

Company Drug

Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review

Fineline Cube Mar 11, 2024

Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s...

Policy / Regulatory

China Cracks Down on Medical Insurance Fraud with New Guidelines and Increased Prosecutions

Fineline Cube Mar 11, 2024

China’s Supreme People’s Court, along with the Supreme People’s Procuratorate and the Ministry of Public...

Company Drug

FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind

Fineline Cube Mar 11, 2024

The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...

Company Drug

Amgen Reports Positive Results for Otezla in Pediatric Psoriasis Trial

Fineline Cube Mar 11, 2024

Amgen (NASDAQ: AMGN) provided an update last week on a late-stage trial evaluating its PDE4...

Company

Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges

Fineline Cube Mar 8, 2024

Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...

Company

GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic

Fineline Cube Mar 8, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that...

Company Drug

BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment

Fineline Cube Mar 8, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Drug

BeiGene’s Brukinsa Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 8, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biotech company based in China,...

Company Drug

Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA

Fineline Cube Mar 8, 2024

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo...

Company Deals

Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology

Fineline Cube Mar 8, 2024

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China,...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Drug

Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024

Fineline Cube Mar 8, 2024

Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...

Company Drug

China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833

Fineline Cube Mar 8, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Posts pagination

1 … 426 427 428 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.